Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.
Although diagnostic testing is not currently regulated by the FDA, payers will commonly take a look at what’s going on in other areas where there is FDA approval and determine what sorts of signals can come from claims data and other information, said Bryan Loy, MD, MBA.
“Having some processes in place to not only measure signals, but also how folks are using the test and the results has become very important,” he said.
Daniel Hayes, MD, added that he hopes CancerLinQ from the American Society of Clinical Oncology will ensure that physicians are using tests properly, which is a matter of education and training.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More